Virtual Network's Login.
23rd John Goldman Conference on
Chronic Myeloid Leukemia: Biology and Therapy
GOING VIRTUAL
NEW DATES: October 7-10, 2021
#ESHCML2021
Chairs: J. Cortes, T. P. Hughes, D. S. Krause
Organizers: R. Bhatia, T. Brümmendorf, M. Copland, M. Deininger, O. Hantschel, F.X. Mahon, D. Perrotti, J. Radich, D. Réa
Advisory Committee: J. Apperley, S. Branford, C. Gambacorti-Passerini, F. Guilhot, R. Hehlmann, P. Laneuville, G. Saglio, C. Schiffer, S. Soverini, P. Valent, R. Van Etten
ABOUT THE CONFERENCE
In view of continuing COVID-19 related challenges, the 23rd John Goldman Conference on CML will be held as a virtual event.
REGISTRATION IS OFFERED FREE OF CHARGE as a gesture of solidarity during these difficult times.
ABOUT THE PROGRAM:
Speakers at this meeting will present the newest and often unpublished data relating to the (1) Biology of CML including the origin of BCR-ABL1, signal transduction, basis of disease progression, action of tyrosine kinase inhibitors and mechanisms underlying resistance to TKI, and (2) aspects of treatment including prediction and definition of responses, drugs used in combination, modern diagnostics and molecular monitoring, targeting residual stem cells, approaches to cure and treatment free remission.
The Program will include:
Educational Objectives:
Upon completion of this CME activity, participants should be able to:
1. Understand current and new concepts of the signal transduction pathways involved in chronic myeloid leukemia (CML) and the mechanisms of action of tyrosine kinase inhibitors and other new agents.
2. Have insight into the possible mechanisms of genomic instability that predisposes to formation of the BCR-ABL fusion gene and predispose also to disease progression and the consequences of such instability.
3. Define a leukemia stem cell and its relationship to disease kinetics in so far as current knowledge permits.
4. Evaluate the merits of various management decisions, e.g. how to start treatment for patients in the different phases of CML, how to assess success or failure of initial treatment, what approaches to consider for patients who have failed to respond well to initial treatment, including assessing the precise role of second and third generation TKIs and other non-molecular therapeutic approaches.
5. Review the current recommendations and discuss current concepts and challenges of monitoring individual patients with hematologic, cytogenetic and molecular (RQ-PCR) methods.
6. Assess the role of allogeneic stem cell transplantation in the management of CML.
7. Critically evaluate the possible role of the different immunotherapeutic approaches in the treatment of CML.
8. Discuss current data and ongoing research regarding treatment-free survival as an endpoint in CML management.
9. Discuss patient reported outcomes and their role in the management of patients with CML.
ABSTRACTS SUBMISSION IS NOW CLOSED
Abstracts guidelines:
– Your abstract has to be structured (eg Objectives, Methods, Results, Conclusions)
– Maximum number of words: 500
– Your abstract will be submitted to the peer review procedure.
The following file types may be uploaded: HTML document (*.htm), HTML document (*.html), JPEG image (*.jpg), GIF image (*.gif), or PNG image (*.png).
TO ACCESS THE E-CONFERENCE PLATFORM CLICK HERE
Take a vitual tour of the E-Conference platform and make yourself at home!
With the support of*:
Emerald E-Conference Partners
*********
Ruby E-Conference Partner
*********
*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.
The registration fee for the 23rd John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy is free.
Meet the Expert sessions: Registration fee: 20€
These sessions are open to E-Conference academic biologists and clinicians registrants only. A maximum of 30 seats is available in each session and pre-registration is therefore be required.
